Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) is a developer of exoskeleton and rehabilitation technologies for medical and industrial applications, and its news flow reflects this focus. Company press releases highlight product and technology developments, capital markets activity, strategic partnerships, and financial performance. Ekso Bionics regularly describes itself as an industry leader in exoskeleton technology that supports or enhances human strength, endurance, and mobility, with an emphasis on improving health and quality of life.
News updates for EKSO often cover clinical and rehabilitation initiatives, such as the launch of eksoUniversity, a virtual platform offering continuing education courses for physical therapists and physical therapy assistants who work with patients with neurological conditions. Other announcements detail agreements like Ekso Bionics’ role as the exclusive authorized U.S. sales agent and distributor for MediTouch’s BalanceTutor rehabilitation system, which uses a patented 4D perturbation treadmill and multiple sensors to help patients with impaired balance respond to unexpected disturbances while walking.
Investors and observers can also find coverage of Ekso Bionics’ technology roadmap, including its acceptance into the NVIDIA Connect program and related efforts to build a proprietary foundation model for human motion and integrate AI-enabled capabilities into its Enterprise Health and Personal Health exoskeleton devices. The company has reported proof-of-concept for an AI voice agent, Ekso Voice Agent, designed for intelligent control of its legacy EksoNR device.
In addition, EKSO news includes quarterly financial results, reverse stock split announcements, registered direct offerings of common stock, and secured loan agreements. Together, these updates provide insight into the company’s operating trends, capital structure decisions, and strategic priorities. This news page aggregates such disclosures so readers can follow developments in Ekso Bionics’ exoskeleton, rehabilitation, and AI initiatives over time.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported financial results for Q1 2022, achieving $2.6 million in revenue, up from $1.9 million in Q1 2021. The company booked 23 EksoNR units and secured its largest multi-unit order. Gross profit dropped by 2% to $1.2 million, decreasing gross margin to 47% due to increased service costs. Net loss grew to $4.6 million, or $0.36 per share, compared to a loss of $3.7 million in Q1 2021. Cash reserves were $36.2 million as of March 31, 2022, down from $40.4 million at year-end 2021.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced it will release its first quarter 2022 financial results on April 28, 2022, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and business developments. Investors can access the live webcast through the company's website, with a replay available for one month post-event. Ekso Bionics specializes in exoskeleton technology, enhancing human strength and mobility in various applications.
Ekso Bionics Holdings reported a record revenue of $4.1 million for Q4 2021, up from $2.3 million in Q4 2020. The company achieved a gross margin of approximately 59%. They booked 30 EksoNR units and posted a reduced net loss of $2.9 million, down from $4.0 million YoY. For the full year, revenue was $11.2 million, marking a 27% increase from 2020. Cash on hand rose to $40.4 million. Management appointed Steven Sherman as CEO and Scott Davis as President/COO, emphasizing their focus on innovation in neurorehabilitation.
Ekso Bionics Holdings (Nasdaq: EKSO) will release its financial results for Q4 and full year 2021 on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. The live webcast will be accessible on the company's website. Founded in 2005, Ekso Bionics specializes in exoskeleton technology aimed at enhancing mobility and strength in medical and industrial sectors.
Ekso Bionics Holdings announced the departure of CEO Jack Peurach effective January 21, 2022, to pursue other endeavors. Steven Sherman, the current Chairman, will step in as CEO starting January 22, 2022, while Scott Davis is promoted to President and COO. The board expressed confidence in future growth after reporting record revenue for Q4, driven by momentum in rehabilitation and industrial segments. Sherman aims to expand the product portfolio and align his compensation with shareholder interests by opting for equity over cash salary.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported record preliminary revenue for Q4 2021 between $3.9 million and $4.1 million, showing a 77% increase from Q4 2020's $2.3 million. Total revenue for fiscal 2021 reached an estimated $11.1 million to $11.3 million, up 26% from $8.9 million in 2020. Cash on hand surged to $40.4 million from $12.9 million a year earlier. CEO Jack Peurach indicated strong growth in both rehabilitation and industrial sectors, enhancing their market presence.
Ekso Bionics, a leader in exoskeleton technology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The management will engage in a fireside chat available on-demand starting January 10 at 4:00 AM PT. This chat will be accessible throughout the conference on the company's investor website. Founded in 2005, Ekso Bionics aims to enhance strength and mobility through innovative wearable robots. The company is publicly traded on Nasdaq under the symbol EKSO.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has appointed Corinna E. Lathan, Ph.D., to its Board of Directors. Dr. Lathan brings over 20 years of experience in robotics and biomedical engineering, having co-founded AnthroTronix. She currently serves on the board of PTC, Inc. and has held academic positions at prominent universities. CEO Jack Peurach expressed confidence in Dr. Lathan's ability to provide unique insights as the company aims to advance its innovative exoskeleton technologies for medical and industrial applications.
Ekso Bionics Holdings announced a significant partnership with the Fraternal Order of Eagles to enhance patient care in Nebraska. The EksoNR devices will be donated to Bryan Medical Center and Nebraska Methodist Hospital, benefiting over 60% of patients. This innovative technology aims to improve rehabilitation outcomes for patients with spinal cord injuries, strokes, and brain injuries. The initiative underscores Ekso's commitment to advanced rehabilitation and support for healthcare providers.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported a revenue of $3.0 million for Q3 2021, a slight increase from $2.9 million in Q3 2020. The gross margin was approximately 59%, down from 63% the previous year. The company booked 16 EksoNR units and maintained a strong cash position of $43.4 million. Despite increased revenues from EksoHealth, the net loss applicable to common stockholders for the quarter was $2.0 million, contrasting with a net income of $2.5 million during the same period in 2020.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
